ANALYSIS OF THE EFFICIENCY OF ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS C VIRUS INFECTION

Objective. To analyze treatment results in patients with chronic hepatitis C (CHC) according to the EASL recommendations. Subjects and methods. Fifty-f ive patients aged 21 to 63 years with CHC were followed up. Of them, 11 patients were diagnosed as having Child-Pugh Class A hepatitis C virus-related cirrhosis. Results. The CHC patients were most frequently found to have genotypes 1b (36%) and 3a (36%); genotype 2a was identified in 19% of the patients; CHC genotype was not determined in 9%. The patients with liver cirrhosis showed a preponderance of genotype 3a in 8 cases; genotype 1a was revealed in 3 patients. A sustained virologic response was achieved in only 40% of the patients with genotype 1b, in 80% of those with genotypes 2a and 3a, and in 60% of those with an uncertain genotype. The most common adverse effects of antiviral therapy should include itching and eczema in 23.6% of the patients and varying hematological problems that developed in 74.5% at 9-12 weeks of therapy. Conclusion. It was noted that antiviral therapy was inadequately effective in patients with CHC genotype 1b and the low efficiency of therapy was closely related to significant hepatic fibrosis.

hepatitis C, antiviral therapy